Portfoliotracker

AbbVie Inc.: Q3 2026 results

Published 29. 10. 2026, before the market opens. EPS – against an estimate of 3,84.

Company page

AI summary

AI
Order an AI summary of these results Vytvoří se jednou na pozadí a pak ho uvidí všichni. Ve verzi Free 3 objednávky měsíčně.

The summary shows how the results turned out, what the company delivered, the pros and cons and why the stock reacted the way it did.

Company press release

Open on the SEC website

The transcript of the analyst call is protected by copyright, so we show the public press release here.

Show the full text
EX-99.1
2
abbv-20260930nonxgaapxex991.htm
EX-99.1

AbbVie Inc.

Guidance Including the Impact of Acquired IPR&D and Milestones Expense

(Unaudited)

|

| (in millions, except per share data) | Quarter Ended September 30, 2026 | Full-Year Ended December 31, 2026

| Acquired IPR&D and Milestones Expense | Adjusted Diluted EPS Range | Acquired IPR&D and Milestones Expense | Adjusted Diluted EPS Range

| Low | High | Low | High

|
Previously announced guidance excluding Q3 2026 acquired IPR&D and milestones expense
| $ | — | $ | 3.84 | $ | 3.88 | $ | 1,035 | $ | 13.87 | $ | 14.07 |

| Q3 2026 acquired IPR&D and milestones expense | 216 | (0.11) | (0.11) | 216 | (0.11) | (0.11) |

|
Guidance including Q3 2026 acquired IPR&D and milestones expensea
| $ | 216 | $ | 3.73 | $ | 3.77 | $ | 1,251 | $ | 13.76 | $ | 13.96 |

a The Company's 2026 adjusted diluted EPS guidance excludes any impact from acquired IPR&D and milestones expense that may be incurred beyond the third quarter of 2026, as both cannot be reliably forecasted.

1

Your own portfolio, properties and finances in one place.

The account is free with no time limit. Only you see your data; nobody adds it up with others.

This is saved to your account. You can keep browsing, calculating and comparing without signing in.

Welcome back

Sign in and pick up where you left off.

or continue with

No account yet? Create a free account